Teclistamab Dosing and Adverse Event Prophylaxis Practices
Following a review of recent data from MajesTEC-1 investigating teclistamab, the panel provides clinical insights on dosing and adverse event prophylaxis practices.
EP: 1.The Current Treatment Landscape for Relapsed/Refractory Multiple Myeloma
EP: 2.MajesTEC-1: Efficacy and Safety of Teclistamab
Now Viewing
EP: 3.Teclistamab Dosing and Adverse Event Prophylaxis Practices
EP: 4.Clinical Implications of MajesTEC-1
EP: 5.Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma
Video content above is prompted by the following question(s):
- What factors could contribute to the observed decrease in the onset of new grade ≥3 infections over time, and what are the clinical implications?
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
